Nuveen Asset Management LLC Sells 232,335 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Nuveen Asset Management LLC lowered its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 11.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,798,989 shares of the biopharmaceutical company's stock after selling 232,335 shares during the quarter. Nuveen Asset Management LLC owned 1.16% of TG Therapeutics worth $54,150,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of TGTX. Arizona State Retirement System raised its position in shares of TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after acquiring an additional 364 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares during the period. Daymark Wealth Partners LLC boosted its stake in TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after acquiring an additional 689 shares during the period. Finally, New York State Teachers Retirement System boosted its stake in TG Therapeutics by 1.9% in the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after acquiring an additional 837 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

Shares of TGTX stock traded up $0.04 during trading hours on Thursday, reaching $34.24. 1,455,575 shares of the company's stock were exchanged, compared to its average volume of 2,987,319. TG Therapeutics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $5.44 billion, a P/E ratio of -342.37 and a beta of 2.21. The business has a fifty day moving average price of $38.38 and a 200-day moving average price of $34.09.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same period last year, the company earned ($0.07) EPS. The company's revenue was up 90.4% on a year-over-year basis. Analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TGTX has been the topic of several analyst reports. Wall Street Zen upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.